Navigation Links
Dr. Neil Sadick Presents on Pyratine-6(TM) at the Annual Meeting of the American Academy of Dermatology
Date:2/6/2008

NAPA, Calif., Feb. 6 /PRNewswire-FirstCall/ -- Senetek PLC (OTC Bulletin Board: SNKTY), a Life Sciences company engaged in the development of technologies that target the science of healthy aging, today announced that Dr. Neil Sadick presented on Pyratine-6(TM) at the 66th Annual Meeting of the American Academy of Dermatology in San Antonio, Texas.

In his presentation to the Academy, Dr. Sadick, a prominent New York dermatologist, outlined the therapeutic benefits of Senetek's Pyratine-6(TM) for the treatment of aging skin. Dr. Sadick reviewed clinical data demonstrating the ability of Pyratine-6(TM) to ameliorate the visible signs of skin aging and significantly reduce erythema -- redness of the skin caused by capillary congestion.

In independent clinical trials at the University of California, Irvine and RCTS, an independent laboratory in Irving, Texas, Pyratine-6(TM) demonstrated significant efficacy in the treatment of fine wrinkles, skin roughness, acne lesions, overall skin aging, and significantly reduced erythema as early as two weeks from onset of use. Pyratine-6(TM) was also shown to increase skin moisture content and was well tolerated by all subjects producing no measurable skin irritation or signs of allergic contact dermatitis with twice-daily application over the 12-week study periods.

Frank Massino, Chairman and Chief Executive Officer of Senetek stated, "We are very pleased by the recognition Pyratine-6(TM) has received at this important dermatological symposium."

About Senetek PLC

Senetek PLC (OTCBB: SNKTY) is a Life Sciences company engaged in the development of breakthrough technologies that target the science of healthy aging. The Company's extensive research collaborations have resulted in a strong pipeline of patented compounds and products with broad therapeutic applications and a leading presence in dermatology. Senetek collaborates with established specialty pharmaceutical companies in the final development and marketing of its proprietary products, most recently resulting in the development of the best-selling anti-aging product sold in the North American physician market.

For more information, visit the company's website at http://www.senetekplc.com.

This news release contains statements that may be considered 'forward- looking statements' within the meaning of the Private Securities Litigation Reform Act. Forward-looking statements by their nature involve substantial uncertainty, and actual results may differ materially from those that might be suggested by such statements. Important factors identified by the Company that it believes could result in such material differences are described in the Company's Annual Report on Form 10-K for the year 2006. However, the Company necessarily can give no assurance that it has identified or will identify all of the factors that may result in any particular forward-looking statement materially differing from actual results, and the Company assumes no obligation to correct or update any forward-looking statements which may prove to be inaccurate, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Senetek PLC
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Bush Budget Represents Double Whammy Hit on U.S. Seniors Medicare-Financed Nursing Facility Care
2. Womans Day Presents the 5th Annual Red Dress Awards Honoring Women Who Are Leaders in the Fight Against Heart Disease
3. Center for Science Writings presents: Big Fat Lies: The Truth about Diet, Exercise and Obesity
4. IQWiG presents a concept for cost-benefit assessment methods in the German health care system
5. Illness Presents Diabetics With Special Challenges
6. A New Book on Sexual Medicine Calls Attention to The Couple and Presents State-of-the Art Treatments for Sexual Dysfunction
7. GlaxoSmithKline Presents Innovative Neuroscience Pipeline
8. EntreMed Presents Results for ENMD-1198 and Vincristine in Preclinical Leukemia Models
9. New book presents comprehensive survey of research into the molecular basis of aging
10. NHCAA Presents 2007 Fraud Investigation of the Year Award to U.S. Departments of Justice, HHS, and Treasury for Convicting Internet Pharmacy Drug Kingpin
11. National Partners from St. Jude Halloween Promotion Presents More Than $1.7 Million to Help Fight Childhood Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/17/2017)... ... 2017 , ... Pharmica Consulting attended CHI's 8th Annual SCOPE ... trial planning and management. Pharmica discussed the importance of effective project management, data ... by Pharmica’s booth were able to demo its cloud-based Resource Management Tool, ...
(Date:2/17/2017)... ... 17, 2017 , ... Like most hospitals across the nation, Onslow Memorial Hospital ... the Hospital Readmission Reduction Program (HRRP), the return of a patient to the hospital ... the nation. While many providers are struggling to leverage limited resources and technology, Onslow ...
(Date:2/17/2017)... Plantation, FL (PRWEB) , ... February 17, 2017 ... ... protection services and financial planning assistance to families and business owners in the ... the LifeNet 4 Families organization. , For more than 30 years, LifeNet ...
(Date:2/16/2017)... ... February 17, 2017 , ... Teaching nursing care of vulnerable children is ... ACE.P (pediatrics) is being created with the support of the Hearst Foundations. An initiative ... ACE.P will address what has been identified as a critical gap in preparing the ...
(Date:2/16/2017)... , ... February 16, 2017 , ... ... highly regarded orthopedic surgeon, Dr. Raj, to their network through his work at ... Chemistry from Dalhousie University, and his medical degree from Canada’s prestigious International Baccalaureate ...
Breaking Medicine News(10 mins):
(Date:2/18/2017)... , Feb. 17, 2017 Research and Markets has ... report to their offering. ... The report provides separate comprehensive analytics for the US, ... , Asia-Pacific , Latin America , ... period 2015 through 2022. Also, a six-year historic analysis is provided for ...
(Date:2/17/2017)... , Feb. 17, 2017 Arvinas LLC, ... drugs based on protein degradation, today announced the presentation ... (AR) PROTAC during a poster session at the American ... GU) in Orlando, FL. ... validate our platform and the potential of PROTACs to ...
(Date:2/17/2017)... , Feb. 17, 2017   Risperdal lawsuits involving ... allegedly associated with use of the atypical antipsychotic medication ... Court of Common Pleas, where the state,s ... program. According to a notice posted on the ... a meeting on March 9, 2017 at 11:00 a.m. ...
Breaking Medicine Technology: